Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Hepatology
    July 2024

  1. Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
    Hepatology. 2024;80:E23.
    >> Share


  2. Hepatology Highlights.
    Hepatology. 2024;80:1-2.
    >> Share

  3. LAINE L, Barkun AN, Leontiadis GI
    Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
    Hepatology. 2024;80:E15-E16.
    >> Share

  4. KRAWCZYK M, Lammert F
    Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
    Hepatology. 2024;80:E11-E12.
    >> Share

  5. RINELLA ME, Lazarus JV, Newsome PN
    Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
    Hepatology. 2024;80:E13-E14.
    >> Share

  6. MA J, Liangpunsakul S
    Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
    Hepatology. 2024;80:14-17.
    >> Share

  7. DAVENPORT M
    Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
    Hepatology. 2024;80:18-19.
    >> Share

  8. WOLTERS F, Oude Elferink RPJ, Beuers U
    PPARalpha, PPARdelta, or both-that is the question!
    Hepatology. 2024;80:8-10.
    >> Share

  9. KOSHIOL J, Krawczyk M
    enHanCCing knowledge of genetic factors in primary liver tumor.
    Hepatology. 2024;80:11-13.
    >> Share

  10. NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
    Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
    Hepatology. 2024;80:E6-E7.
    >> Share

  11. CAO H, Gu J
    Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
    Hepatology. 2024;80:E4-E5.
    >> Share

  12. ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
    Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
    Hepatology. 2024;80:163-172.
    >> Share

  13. FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
    Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
    Hepatology. 2024;80:102-118.
    >> Share

  14. LOPEZ-PASCUAL A
    Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
    Hepatology. 2024;80:20-23.
    >> Share

  15. SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
    Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
    Hepatology. 2024;80:119-135.
    >> Share

  16. TONG Y, Wang F, Li S, Guo W, et al
    Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
    Hepatology. 2024;80:38-54.
    >> Share

  17. SINGAL AK, Shah VH, Malhi H
    Emerging targets for therapy in ALD: Lessons from NASH.
    Hepatology. 2024;80:223-237.
    >> Share


  18. Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    >> Share

    June 2024
  19. LI J, Ma X, Xuan Q, Li Q, et al
    Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
    >> Share

  20. YANG M, Song X, Zhang F, Li M, et al
    Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
    >> Share

  21. LIU Q, Zhang X, Qi J, Tian X, et al
    Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
    Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
    >> Share


  22. Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
    >> Share

  23. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    >> Share


  24. Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
    Hepatology. 2024;79:E171-E172.
    >> Share


  25. Hepatology Highlights.
    Hepatology. 2024;79:1239-1240.
    >> Share

  26. LI Z, Zhang Y, Li Y, Lan J, et al
    Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
    Hepatology. 2024;79:E169-E170.
    >> Share

  27. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
    Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:E155-E156.
    >> Share

  28. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
    Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:E153-E154.
    >> Share

  29. YEH JG, Newsome PN
    Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
    Hepatology. 2024;79:1255-1257.
    >> Share

  30. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    >> Share

  31. ABDELMALEK MF, Rinella ME
    Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
    Hepatology. 2024;79:1252-1254.
    >> Share

  32. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
    Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
    Hepatology. 2024;79:1401-1411.
    >> Share

  33. ZHAO G, Ma Q, Yang H, Jiang H, et al
    Base editing of the mutated TERT promoter inhibits liver tumor growth.
    Hepatology. 2024;79:1310-1323.
    >> Share

  34. SCHMIDT KA, Simonetto DA
    The telomere tango: Liver disease in the genomic spotlight.
    Hepatology. 2024;79:1249-1251.
    >> Share

  35. SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
    Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
    Hepatology. 2024;79:1365-1380.
    >> Share

  36. UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
    The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
    Hepatology. 2024;79:1352-1364.
    >> Share

  37. WANG A, Blackford AL, Behling C, Wilson LA, et al
    Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1381-1392.
    >> Share

  38. JIN Y, Shou Y, Lei Q, Du C, et al
    An entropy weight method to integrate big omics and mechanistically evaluate DILI.
    Hepatology. 2024;79:1264-1278.
    >> Share

  39. AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
    Human liver organoids: From generation to applications.
    Hepatology. 2024;79:1432-1451.
    >> Share

    May 2024
  40. MANTOVANI S, Mondelli MU
    Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
    >> Share

  41. GUO C, Liu Z, Zhang T
    Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
    >> Share

  42. MUSSO G, Pinach S, Mariano F, Saba F, et al
    Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
    >> Share

  43. MOORE MP, Wang X, Kennelly JP, Shi H, et al
    Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
    Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
    >> Share

  44. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
    Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1212-1219.
    >> Share

  45. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
    Hepatology. 2024;79:E130-E131.
    >> Share

  46. ZAHRAWI FM, Mehal WZ
    Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
    Hepatology. 2024;79:E129.
    >> Share

  47. STOCKDALE AJ, Degasperi E
    HDV RNA and liver disease progression: What do we know?
    Hepatology. 2024;79:983-985.
    >> Share

  48. DESERT R, Foucher F, Guillout M, Nieto N, et al
    Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E141-E143.
    >> Share

  49. WANG TC, Xiao YD, Zhou P
    Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E140.
    >> Share

  50. LIU H, Li H, Wang DX, Li T, et al
    Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:E144-E145.
    >> Share

  51. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
    Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hepatology. 2024;79:E146-E147.
    >> Share

  52. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
    Hepatology. 2024;79:1065-1074.
    >> Share

  53. SQUIRES JE, Horslen SP
    Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
    Hepatology. 2024;79:970-972.
    >> Share

  54. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
    Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:1107-1116.
    >> Share

  55. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
    Genetic landscape of pediatric acute liver failure of indeterminate origin.
    Hepatology. 2024;79:1075-1087.
    >> Share

  56. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
    Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Hepatology. 2024;79:1098-1106.
    >> Share

  57. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
    Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
    Hepatology. 2024;79:1141-1157.
    >> Share

  58. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
    Spatial metabolomics and its application in the liver.
    Hepatology. 2024;79:1158-1179.
    >> Share


  59. Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
    Hepatology. 2024;79:E150-E151.
    >> Share

    April 2024
  60. KUMAR M, Venishetty S
    Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
    Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
    >> Share

  61. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
    Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
    >> Share

  62. LI X, Zhang Y, Li S, Shi J, et al
    Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
    >> Share

  63. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
    Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
    >> Share

  64. LEE YT, Tseng HR, Yang JD
    Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
    Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
    >> Share

  65. GUO C, Liu Z, Fan H, Wang H, et al
    Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
    >> Share

  66. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
    ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
    >> Share

  67. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
    Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
    >> Share

  68. GARCIA-TSAO G, Kaplan DE
    Reply: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
    >> Share

  69. VOLK ML
    Innovations in Healthcare Delivery for Patients with Cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
    >> Share

  70. MOGHE A, McGuire BM, Levy C
    Acute hepatic porphyrias - a guide for Hepatologists.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
    >> Share

  71. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
    Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
    Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
    >> Share

  72. LI J, Allen AM, Yin M
    Reply: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E121-E122.
    >> Share

  73. ALKHOURI N, Harisinghani M
    Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E119-E120.
    >> Share

  74. FRANSES JW, Duda DG
    Scirrhous HCC: Another 'omic thread in the HCC tapestry.
    Hepatology. 2024;79:747-748.
    >> Share

  75. VOLKERT I, Fromme M, Schneider C, Candels L, et al
    Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Hepatology. 2024;79:898-911.
    >> Share

  76. LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
    Mechanisms of drug resistance in HCC.
    Hepatology. 2024;79:926-940.
    >> Share


  77. Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
    Hepatology. 2024;79:E128.
    >> Share


  78. Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
    Hepatology. 2024;79:E127.
    >> Share


  79. April 2024 Hepatology Highlights.
    Hepatology. 2024;79:745-746.
    >> Share

  80. TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
    Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
    >> Share

  81. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
    Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
    >> Share

    March 2024

  82. Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
    Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
    >> Share

  83. DENG T, Chen G
    Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
    >> Share

  84. CRUZ C, Prado CM, Gillis C, Martindale R, et al
    Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
    >> Share

  85. FENG X, Feng B, Zhou J, Yang J, et al
    Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
    >> Share

  86. GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
    Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
    >> Share

  87. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
    NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
    >> Share

  88. CHEN Y, Deng X, Li Y, Han Y, et al
    Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
    >> Share

  89. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
    The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
    >> Share

  90. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
    A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
    >> Share

  91. MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
    Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
    >> Share

  92. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
    AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
    >> Share

  93. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
    AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
    >> Share

  94. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
    AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
    >> Share

  95. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
    Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
    >> Share

  96. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
    Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
    >> Share

  97. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
    Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
    >> Share

  98. BU W, Sun X, Xue X, Geng S, et al
    Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
    >> Share

  99. MUNOZ AE, Rodger EG
    Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
    >> Share

  100. SHARPTON S, Loomba R
    Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
    >> Share

  101. GUO Q, Wang J, Wang G, Wang X, et al
    Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
    Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
    >> Share

  102. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    >> Share

  103. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
    Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
    >> Share

  104. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    >> Share

  105. ROY A, Kajal K, Izzy M, Sihag BK, et al
    Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
    >> Share

  106. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
    Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
    >> Share


  107. Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
    Hepatology. 2024;79:E105.
    >> Share

  108. HOOFNAGLE JH, Doo E
    Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E91-E92.
    >> Share

  109. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E93-E94.
    >> Share

  110. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
    Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E87-E88.
    >> Share

  111. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
    Reply: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E89-E90.
    >> Share

  112. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
    Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
    Hepatology. 2024;79:624-635.
    >> Share

  113. WANG F, Chen L, Kong D, Zhang X, et al
    Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
    Hepatology. 2024;79:606-623.
    >> Share

  114. LEE BP, Dodge JL, Terrault NA
    National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Hepatology. 2024;79:666-673.
    >> Share

  115. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
    Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
    Hepatology. 2024;79:551-559.
    >> Share

  116. LEDENKO M, Antwi SO, Patel T
    Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
    Hepatology. 2024;79:575-588.
    >> Share

  117. LEVY C, Dickey AK, Wang B, Thapar M, et al
    Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
    Hepatology. 2024;79:731-743.
    >> Share


  118. Hepatology Highlights.
    Hepatology. 2024;79:525-526.
    >> Share

    February 2024
  119. WONG YJ, Teng M, Sim A, Thet HM, et al
    Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
    >> Share

  120. HASSAN MM, Li D, Han Y, Byun J, et al
    Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
    >> Share

  121. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    >> Share

  122. PENG Z, Wei G, Huang P, Matta H, et al
    ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
    >> Share

  123. HE B, Huang Z, Qin S, Peng P, et al
    Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
    >> Share

  124. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
    A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
    Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
    >> Share

  125. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
    Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
    >> Share

  126. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    >> Share

  127. ZHU M, Liu Z, Chen S, Luo Z, et al
    Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
    >> Share

  128. PARK JG, Roh PR, Kang MW, Cho SW, et al
    Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
    >> Share

  129. DONGELMANS E, Erler N, Adam R, Nadalin S, et al
    Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
    >> Share

  130. AGRAWAL D, Ariga KK
    Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
    >> Share

  131. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
    From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
    >> Share

  132. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    >> Share

  133. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
    Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
    Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
    >> Share

  134. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
    Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
    Hepatology. 2024;79:E16-E17.
    >> Share

  135. CUSI K, Younossi Z, Roden M
    From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
    Hepatology. 2024;79:E13-E15.
    >> Share

  136. BALAKRISHNAN M, Rehm J
    A public health perspective on mitigating the global burden of chronic liver disease.
    Hepatology. 2024;79:451-459.
    >> Share

  137. KHALID M, Khan ZM, Sheraz Kahloon A
    Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
    Hepatology. 2024;79:E18-E19.
    >> Share

  138. KIM Y, Chang Y, Ryu S, Wild SH, et al
    Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
    Hepatology. 2024;79:E20-E21.
    >> Share

  139. BARR RG, Bolondi L
    Contrast-enhanced US for HCC: Finally out from the waiting list?
    Hepatology. 2024;79:267-268.
    >> Share

  140. LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
    Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
    Hepatology. 2024;79:380-391.
    >> Share

  141. HUANG H, Tsui YM, Ho DW, Chung CY, et al
    LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
    Hepatology. 2024;79:323-340.
    >> Share

  142. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
    A global action agenda for turning the tide on fatty liver disease.
    Hepatology. 2024;79:502-523.
    >> Share

  143. MENG Z, Zhou L, Hong S, Qiu X, et al
    Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
    Hepatology. 2024;79:409-424.
    >> Share

  144. SINHA S, Hassan N, Schwartz RE
    Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
    Hepatology. 2024;79:482-501.
    >> Share


  145. Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    >> Share


  146. Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    >> Share

    January 2024

  147. Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
    Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
    >> Share

  148. WANG Y, Wang X, Bai B, Shaha A, et al
    Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
    >> Share

  149. XIA Y, Wang Y, Xiong Q, He J, et al
    Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
    >> Share


  150. Hepatology highlights.
    Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
    >> Share

  151. NAKAGAWA H, Lin A
    The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
    Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
    >> Share

  152. NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
    C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
    Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
    >> Share

  153. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
    Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
    >> Share


  154. Hepatology Highlights.
    Hepatology. 2024;79:1-2.
    >> Share

  155. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    >> Share

  156. EMANUELE E, Minoretti P
    Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
    Hepatology. 2024;79:E4.
    >> Share

  157. NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
    Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
    Hepatology. 2024;79:E5-E6.
    >> Share

  158. ROWE IA
    Prediction of outcomes in patients with acute variceal bleeding.
    Hepatology. 2024;79:15-17.
    >> Share

  159. WANG CC, Cheng YM, Kao JH
    Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
    Hepatology. 2024;79:E7-E8.
    >> Share

  160. GARCIA-CRIADO A, Bruix J
    Screening for liver cancer: The good, the bad, and the ugly.
    Hepatology. 2024;79:12-14.
    >> Share

  161. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    >> Share

  162. LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
    AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
    Hepatology. 2024;79:224-250.
    >> Share


  163. Hepatology Highlights.
    Hepatology. 2024;79:1-2.
    >> Share

    December 2023
  164. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
    Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
    >> Share

  165. VAJRO P, Mandato C
    Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
    >> Share

  166. JENG WJ, Chien RN, Liaw YF
    Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
    >> Share

  167. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    >> Share

  168. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    >> Share

  169. WATT KD, Khan MQ
    Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
    >> Share

  170. CHEN J, Tu T, Cohen C, Wang S, et al
    Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
    >> Share

  171. ZABRANSKY DJ, Yarchoan M, Ho WJ
    Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
    >> Share

  172. LU T, Zhang J, Li H, Li G, et al
    Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
    Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
    >> Share

  173. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    >> Share

  174. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
    Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
    Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
    >> Share

  175. VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
    Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
    Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
    >> Share

  176. SCHULZE RJ, Strom SC, Nyberg SL
    From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
    Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
    >> Share

  177. YU S, Liu X, Xu Y, Pan L, et al
    m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
    Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
    >> Share

  178. YIN C, Zhang C, Wang Y, Liu G, et al
    ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
    Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
    >> Share

  179. CHAN FF, Yuen VW, Shen J, Chin DW, et al
    Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
    Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
    >> Share

  180. MALHI H, Brown RS Jr, Lim JK, Reau N, et al
    Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
    Hepatology. 2023;78:1680-1681.
    >> Share

  181. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
    A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2023;78:1966-1986.
    >> Share

  182. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
    PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
    Hepatology. 2023;78:1788-1799.
    >> Share

  183. ABERG F
    Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
    Hepatology. 2023;78:E101-E102.
    >> Share

  184. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
    Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
    Hepatology. 2023;78:E103-E104.
    >> Share

  185. ZHANG X, Yip TC, Tse YK, Hui VW, et al
    Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
    Hepatology. 2023;78:1816-1827.
    >> Share

  186. GAO R, Li Y, Xu Z, Zhang F, et al
    Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
    Hepatology. 2023;78:1800-1815.
    >> Share


  187. Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
    Hepatology. 2023;78:E110.
    >> Share


  188. Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
    Hepatology. 2023;78:E108.
    >> Share


  189. Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
    Hepatology. 2023;78:E107.
    >> Share

  190. MAIWALL R, Piano S, Singh V, Caraceni P, et al
    Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
    Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
    >> Share


  191. Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
    Hepatology. 2023;78:1682-1683.
    >> Share

    November 2023
  192. HU YX, Diao LT, Hou YR, Lv G, et al
    PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
    Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
    >> Share

  193. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
    Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
    >> Share

  194. MICHALOPOULOS GK
    Hepatocytes of mice and men: Different regenerative signals?
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
    >> Share

  195. KE L, Rui Z, Fukai W, Yunzheng Z, et al
    Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
    >> Share


  196. February 2024 Hepatology Highlights.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
    >> Share

  197. LIU N, Tian J, Steer CJ, Han Q, et al
    MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
    Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
    >> Share

  198. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
    AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
    Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
    >> Share

  199. QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
    Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
    >> Share

  200. BRENNER DA
    Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
    Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
    >> Share

  201. SCHERR AL, Nader L, Xu K, Elssner C, et al
    Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
    Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
    >> Share

  202. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
    Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
    Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
    >> Share

  203. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
    Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
    Hepatology. 2023;78:E91-E92.
    >> Share

  204. ARIAS-LOSTE MT, Crespo J, Iruzubieta P
    Letter to the Editor: Updated guidance on NAFLD screening.
    Hepatology. 2023;78:E89-E90.
    >> Share

  205. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
    Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
    Hepatology. 2023;78:E87-E88.
    >> Share

  206. YANG Z, Ding WX
    The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
    Hepatology. 2023;78:1329-1331.
    >> Share

  207. LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
    It is time to expand the fatty liver disease community of practice.
    Hepatology. 2023;78:1325-1328.
    >> Share

  208. TILG H, Adolph TE, Tacke F
    Therapeutic modulation of the liver immune microenvironment.
    Hepatology. 2023;78:1581-1601.
    >> Share

  209. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    >> Share

  210. WU Q, Pan C, Zhou Y, Wang S, et al
    Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
    Hepatology. 2023;78:1402-1417.
    >> Share

  211. SONG Y, Wei J, Li R, Fu R, et al
    Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
    Hepatology. 2023;78:1433-1447.
    >> Share

  212. CHIU YT, Husain A, Sze KM, Ho DW, et al
    Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
    Hepatology. 2023;78:1368-1383.
    >> Share

  213. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    >> Share

  214. LEE CM, Yoon EL, Kim M, Kang BK, et al
    Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
    >> Share

  215. BRAILLON A, Naudet F
    Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
    Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
    >> Share

    October 2023
  216. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    >> Share

  217. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    >> Share

  218. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
    Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
    >> Share

  219. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    >> Share

  220. SONG Y, Ye T, Roberts LR, Larson NB, et al
    Randomization in hepatology: A review of principles, opportunities, and challenges.
    Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
    >> Share

  221. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
    AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
    >> Share

  222. YANG T, Qu X, Wang X, Xu D, et al
    Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
    >> Share

  223. CHANG CW, Chen YS, Huang CH, Lin CH, et al
    A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
    >> Share

  224. OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
    Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
    >> Share

  225. CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
    Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
    >> Share

  226. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    >> Share

  227. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
    Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
    >> Share

  228. LIAW YF, Jeng WJ, Chien RN
    Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
    >> Share


  229. Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
    >> Share

  230. VONADA A, Wakefield L, Martinez M, Harding CO, et al
    Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
    Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
    >> Share

  231. CHEN P, Dong Z, Zhu W, Chen J, et al
    Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
    Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
    >> Share

  232. MA S, Chew V
    Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
    >> Share

  233. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
    Non-invasive assessment of hepatic decompensation.
    Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
    >> Share

  234. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
    Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
    Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
    >> Share

  235. XANTHAKOS S
    Rising tide of NAFLD in youth: A warning bell and call to action.
    Hepatology. 2023;78:1017-1019.
    >> Share

  236. ANTON A, Shalaby S, Hernandez-Gea V
    Coagulation meets senescence in NASH!
    Hepatology. 2023;78:1023-1025.
    >> Share

  237. YONEDA M, Nakajima A
    The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
    Hepatology. 2023;78:1020-1022.
    >> Share

  238. CHEN W, Sun Y, Chen S, Ge X, et al
    Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
    Hepatology. 2023;78:1118-1132.
    >> Share

  239. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
    Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
    Hepatology. 2023;78:1200-1208.
    >> Share

  240. KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
    What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
    Hepatology. 2023;78:1032-1034.
    >> Share

  241. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
    Intermittent fasting-the future treatment in NASH patients?
    Hepatology. 2023;78:1290-1305.
    >> Share

  242. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
    Predicting liver-related events in NAFLD: A predictive model.
    Hepatology. 2023;78:1240-1251.
    >> Share

  243. SEIMIYA T, Otsuka M, Fujishiro M
    Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
    Hepatology. 2023;78:1009-1011.
    >> Share


  244. Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
    Hepatology. 2023;78:E85.
    >> Share

  245. STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
    Future directions in acute liver failure.
    Hepatology. 2023;78:1266-1289.
    >> Share

  246. HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
    Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
    Hepatology. 2023;78:1168-1181.
    >> Share

  247. KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
    Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
    Hepatology. 2023;78:1106-1117.
    >> Share

  248. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
    Semaphorin 3C exacerbates liver fibrosis.
    Hepatology. 2023;78:1092-1105.
    >> Share

    September 2023
  249. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
    The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
    Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
    >> Share

  250. LI M, Wang L, Cong L, Wong CC, et al
    Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
    >> Share

  251. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
    A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
    >> Share

  252. ZHAO X, Kotha S, Nayyar D, Ma X, et al
    Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
    >> Share

  253. FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
    Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
    Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
    >> Share

  254. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    >> Share

  255. WATT KD, Paul S, Khan MQ, Siddiqui M, et al
    Obesity management for the hepatologist - what to do, how to do it and why.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
    >> Share

  256. CHEN S, Liao C, Hu H, Liao J, et al
    Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
    >> Share

  257. MAESTRI E, Kedei N, Khatib S, Forgues M, et al
    Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
    >> Share

  258. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    >> Share


  259. December 2023 Hepatology Highlights.
    Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
    >> Share

  260. LAZARUS JV, Han H, Mark HE, Alqahtani SA, et al
    The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.
    Hepatology. 2023;78:911-928.
    >> Share

  261. AWAN MZUA, Patel T
    Letter to the Editor: Dynamic risk profiling of HCC recurrence after curative intent liver resection.
    Hepatology. 2023;78:E55.
    >> Share

  262. HUANG CH, Hsieh SY
    More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC.
    Hepatology. 2023;78:706-708.
    >> Share

  263. YOU M, Gao Y, Fu J, Xie R, et al
    Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC.
    Hepatology. 2023;78:943-958.
    >> Share

  264. LLORENTE C, Rungratanawanich W, Liangpunsakul S
    Intestinal dendritic cells, gatekeepers preventing ethanol-induced liver disease.
    Hepatology. 2023;78:697-701.
    >> Share

  265. UCHIDA T, Imamura M, Hayes CN, Suehiro Y, et al
    HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.
    Hepatology. 2023;78:929-942.
    >> Share

  266. GOIKOETXEA-USANDIZAGA N, Bravo M, Egia-Mendikute L, Abecia L, et al
    The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent.
    Hepatology. 2023;78:878-895.
    >> Share

  267. WONG C, Dash A, Fredrickson J, Lewin-Koh N, et al
    Fibroblast growth factor receptor 1/Klothobeta agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.
    Hepatology. 2023;78:847-862.
    >> Share

  268. LAM KH, Ma S
    Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications.
    Hepatology. 2023;78:991-1005.
    >> Share

  269. WU T, Chen X, Xu K, Dai C, et al
    LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
    Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
    >> Share

    August 2023
  270. SHIMADA S, Tanaka S
    The chronicles of hepatocellular carcinoma classification: Subtyping, modeling and treatment.
    Hepatology. 2023 Aug 30. doi: 10.1097/HEP.0000000000000588.
    >> Share

  271. GRATACOS-GINES J, Bruguera P, Perez-Guasch M, Lopez-Lazcano A, et al
    Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000570.
    >> Share

  272. JENG WJ, Chien RN, Chen YC, Lin CL, et al
    Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
    >> Share

  273. CHIN A, Bastaich DR, Dahman B, Kaplan DE, et al
    Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000577.
    >> Share

  274. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
    Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
    Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
    >> Share

  275. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    >> Share


  276. November hepatology highlights.
    Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000565.
    >> Share

  277. KOWALIK MA, Taguchi K, Serra M, Caddeo A, et al
    Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes.
    Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000568.
    >> Share

  278. LV Y, Bai W, Zhu X, Xue H, et al
    Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding.
    Hepatology. 2023 Aug 18. doi: 10.1097/HEP.0000000000000548.
    >> Share

  279. TREBICKA J, Garcia-Tsao G
    Controversies regarding albumin therapy in cirrhosis.
    Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000521.
    >> Share

  280. LI B, Li Y, Zhou H, Xu Y, et al
    Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
    Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000553.
    >> Share

  281. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    >> Share

  282. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    >> Share

  283. HU Y, Li Z, He W, Wang X, et al
    Letter to the Editor: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
    Hepatology. 2023;78:E29-E30.
    >> Share

  284. VAN KLEEF LA, Sonneveld MJ, de Knegt RJ
    Reply: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
    Hepatology. 2023;78:E31-E32.
    >> Share

  285. RONOT M, Nahon P, Rimola J
    Screening of liver cancer with abbreviated MRI.
    Hepatology. 2023;78:670-686.
    >> Share

  286. MCCONNELL MJ, Kostallari E, Ibrahim SH, Iwakiri Y, et al
    The evolving role of liver sinusoidal endothelial cells in liver health and disease.
    Hepatology. 2023;78:649-669.
    >> Share

  287. AN J, Oh JH, Oh B, Oh YJ, et al
    Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient hepatocellular carcinoma.
    Hepatology. 2023;78:452-467.
    >> Share

  288. GUO X, Tan S, Wang T, Sun R, et al
    NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity.
    Hepatology. 2023;78:468-485.
    >> Share

    July 2023
  289. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    >> Share

  290. SENZOLO M, Shalaby S, Grasso M, Vitale A, et al
    Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000538.
    >> Share

  291. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    >> Share

  292. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
    Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
    Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.
    >> Share


  293. October Hepatology Highlights.
    Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000543.
    >> Share

  294. MA X, Ding WX
    Reply: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000541.
    >> Share

  295. HU X, Shen J, Wang T, Liu M, et al
    Letter to the Editor: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitichondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000540.
    >> Share


  296. Retraction: Protein kinase a-dependent pSer675-beta-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000486.
    >> Share

  297. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
    Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000536.
    >> Share

  298. XIANG X, Hao Y, Cheng C, Hu H, et al
    A TGF-beta-dominant chemo-resistant phenotype of hepatoblastoma associated with aflatoxin exposure in children.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000534.
    >> Share

  299. HU Y, Li Z, He W, Wang X, et al
    Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000533.
    >> Share

  300. NARASIMMAN M, Hernaez R, Cerda V, Lee M, et al
    Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis.
    Hepatology. 2023 Jul 4. doi: 10.1097/HEP.0000000000000528.
    >> Share

  301. IAVARONE M, Nault JC, Cabibbo G, Torres F, et al
    Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology.
    Hepatology. 2023 Jul 3. doi: 10.1097/HEP.0000000000000527.
    >> Share


  302. A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
    Hepatology. 2023;78:3-5.
    >> Share

  303. CHEEMA MRS
    Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2023;78:E18.
    >> Share

  304. LEE J, Westphal M, Vali Y, Boursier J, et al
    Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
    Hepatology. 2023;78:258-271.
    >> Share

  305. WEGERMANN K, Diehl AM
    Population-based proteomics: Platforms to advance diagnosis and treatment of metabolic liver diseases.
    Hepatology. 2023;78:8-9.
    >> Share

  306. CHE Y, Chen G, Guo Q, Duan Y, et al
    Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
    Hepatology. 2023;78:88-102.
    >> Share

  307. IRFAN R, Kumar S
    Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2023;78:E8.
    >> Share

  308. PENNISI G, Enea M, Falco V, Aithal GP, et al
    Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
    Hepatology. 2023;78:195-211.
    >> Share

  309. DO A, Lim JK
    Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI.
    Hepatology. 2023;78:6-7.
    >> Share

  310. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).
    Hepatology. 2023;78:272-283.
    >> Share

  311. ABOZAID YJ, Ayada I, van Kleef LA, Vallerga CL, et al
    Plasma proteomic signature of fatty liver disease: The Rotterdam Study.
    Hepatology. 2023;78:284-294.
    >> Share

  312. KONG M, Dong W, Kang A, Kuai Y, et al
    Regulatory role and translational potential of CCL11 in liver fibrosis.
    Hepatology. 2023;78:120-135.
    >> Share

  313. GUO C, Liu W, Liu Z, Cai J, et al
    Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
    Hepatology. 2023;78:45-57.
    >> Share

  314. ZHU H, Yang B
    Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
    Hepatology. 2023;78:E3.
    >> Share

  315. VERMA M, Brahmania M, Fortune BE, Asrani SK, et al
    Patient-centered care: Key elements applicable to chronic liver disease.
    Hepatology. 2023;78:307-318.
    >> Share


  316. July 2023 Hepatology Highlights.
    Hepatology. 2023;78:1-2.
    >> Share

    June 2023

  317. September Hepatology highlights.
    Hepatology. 2023 Jun 13. doi: 10.1097/HEP.0000000000000515.
    >> Share

  318. PINTER M, Reig M, Cabibbo G
    Analysis of individual patient data in patients with hepatocellular carcinoma treated with immunotherapy: A step forward for clinical trial design.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000511.
    >> Share

  319. DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
    Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000513.
    >> Share

  320. TAPPER EB, Lai JC
    Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000508.
    >> Share

  321. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    >> Share

  322. YIM SY, Lee JS
    Reply: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000501.
    >> Share

  323. HENRY L, Younossi ZM
    Reply: NAFLD/MAFLD: One size does not fit all, certainly not for children!
    Hepatology. 2023;77:E191.
    >> Share

  324. HEGARTY R, Dhawan A
    Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!
    Hepatology. 2023;77:E190.
    >> Share

  325. SARKAR M, Flemming JA
    Letter to the Editor: Influence of maternal NAFLD on infant weight-the real precursor to NAFLD in offspring?
    Hepatology. 2023;77:E180.
    >> Share

  326. LEE JM, Joo I
    The international quest for the imaging diagnosis of liver cancer.
    Hepatology. 2023;77:1839-1842.
    >> Share

  327. CANNELLA R, Dioguardi Burgio M, Sartoris R, Gregory J, et al
    Adherence to LI-RADS and EASL high-risk population criteria: A systematic review.
    Hepatology. 2023;77:1958-1967.
    >> Share

  328. BOMMENA S, Mahmud N, Boike JR, Thornburg BG, et al
    The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study.
    Hepatology. 2023;77:2041-2051.
    >> Share

  329. HSU CL, Lang S, Demir M, Fouts DE, et al
    Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
    Hepatology. 2023;77:2073-2083.
    >> Share

  330. NAGALO BM, Zhou Y, Loeuillard EJ, Dumbauld C, et al
    Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
    Hepatology. 2023;77:1943-1957.
    >> Share

  331. LIM M, Muquith M, Miramontes B, Lee CJ, et al
    Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
    Hepatology. 2023 Jun 1. doi: 10.1097/HEP.0000000000000494.
    >> Share

    May 2023
  332. AWAN MZUA
    Letter to the editor: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000493.
    >> Share

  333. JESUDIAN AB, Fortune BE
    The PROs and cons of crystalline lactulose for suspected covert hepatic encephalopathy among patients with cirrhosis and activity impairment: Are we using the right assessments?
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000497.
    >> Share

  334. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    >> Share


  335. Erratum: Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Hepatology. 2023 May 26. doi: 10.1097/HEP.0000000000000450.
    >> Share

  336. CARR RM, Li Y, Chau L, Friedman ES, et al
    An integrated analysis of fecal microbiome and metabolomic features distinguish Non-cirrhotic NASH from healthy control populations.
    Hepatology. 2023 May 25. doi: 10.1097/HEP.0000000000000474.
    >> Share

  337. GILGENKRANTZ H, Paradis V, Lotersztajn S
    Cell metabolism-based therapy for liver fibrosis, repair and hepatocellular carcinoma.
    Hepatology. 2023 May 23. doi: 10.1097/HEP.0000000000000479.
    >> Share

  338. LV Y, Han G
    Reply: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
    Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000475.
    >> Share

  339. YIN HJ, Wan YM
    Letter to the editor: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
    Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000476.
    >> Share

  340. KIM BK, Bergstrom J, Loomba R, Tamaki N, et al
    Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study.
    Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470.
    >> Share


  341. August Hepatology Highlights.
    Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000468.
    >> Share

  342. SINGAL AG, Llovet JM, Yarchoan M, Mehta N, et al
    AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000466.
    >> Share

  343. TONON M, Balcar L, Semmler G, Calvino V, et al
    Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
    Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
    >> Share

  344. VITTAL A, Niewisch MR, Bhala S, Kudaravalli P, et al
    Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000461.
    >> Share

  345. HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
    Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
    >> Share

  346. MALLET M, Silaghi CA, Sultanik P, Conti F, et al
    Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000456.
    >> Share

  347. JI J, Ji F, Bayarsaikhan E
    Intratumoral microbiota in hepatocellular carcinoma: A new kid on the block?
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000454.
    >> Share

  348. ANDRISANI O
    Two important players in poor prognosis hepatocellular carcinoma (HCC): Extrachromosomal circular DNA (eccDNA) and its passenger, the oncogenic miR-17~92 locus.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000453.
    >> Share

  349. MEHTA N, Kelley RK, Yao FY
    Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000452.
    >> Share


  350. Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    >> Share

  351. KANZAKI H, Katz C, Hoshida Y
    Matrisomic characterization of hepatocellular carcinoma to inform individualized patient management.
    Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000443.
    >> Share

  352. ANSTEE QM, Lucas KJ, Francque S, Abdelmalek MF, et al
    Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study.
    Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000439.
    >> Share

  353. LI G, Chen H, Shen F, Smithson SB, et al
    Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis.
    Hepatology. 2023 May 3. doi: 10.1097/HEP.0000000000000433.
    >> Share

  354. SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
    Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Hepatology. 2023;77:1702-1711.
    >> Share

  355. EBRAHIMI F, Ludvigsson JF
    Letter to the editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2023;77:E107-E108.
    >> Share

  356. RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
    AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
    Hepatology. 2023;77:1797-1835.
    >> Share

  357. KNIGHT GM, Thornburg B, Salem R
    Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
    Hepatology. 2023;77:E93-E94.
    >> Share

  358. GU W, Queck A, Trebicka J, Praktiknjo M, et al
    Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
    Hepatology. 2023;77:E101.
    >> Share

  359. ARTRU F, Rautou PE, Denys A
    Letter to the editor: discussing the place of TIPS in noncirrhotic patients with chronic extrahepatic portal vein occlusion (EHPVO).
    Hepatology. 2023;77:E91-E92.
    >> Share

  360. BERARDI G, Ratti F, Sposito C, Nebbia M, et al
    Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.
    Hepatology. 2023;77:1527-1539.
    >> Share

  361. CUCCHETTI A, Casadei-Gardini A
    Liver resection for HCC in patients with metabolic syndrome: questions answered, questions raised.
    Hepatology. 2023;77:1463-1464.
    >> Share

  362. WEN Y, Emontzpohl C, Xu L, Atkins CL, et al
    Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis.
    Hepatology. 2023;77:1580-1592.
    >> Share

  363. ZHANG S, Wan D, Zhu M, Wang G, et al
    CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
    Hepatology. 2023;77:1612-1629.
    >> Share

  364. LUO W, Wang Y, Li Y, Zhang T, et al
    Letter to the editor: Adipose lipolysis is important for ethanol to induce fatty liver in the NIAAA murine model of chronic and binge ethanol feeding.
    Hepatology. 2023;77:E88-E89.
    >> Share

  365. ZABRANSKY DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, et al
    Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
    Hepatology. 2023;77:1566-1579.
    >> Share

  366. JUAREZ-FERNANDEZ M, Goikoetxea-Usandizaga N, Porras D, Garcia-Mediavilla MV, et al
    Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
    Hepatology. 2023;77:1654-1669.
    >> Share

  367. MATHUR M, Yeh YT, Arya RK, Jiang L, et al
    Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding.
    Hepatology. 2023;77:1688-1701.
    >> Share

  368. LI S, Xia H, Wang Z, Zhang X, et al
    Intratumoural microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related hepatocellular carcinoma.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000427.
    >> Share

  369. ZOU S, Chen S, Rao G, Zhang G, et al
    Extrachromosomal circular MiR-17-92 amplicon promotes hepatocellular carcinoma.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000435.
    >> Share

  370. AHMED A, Arshad MW, Ibrahim H
    Letter to the editor: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000429.
    >> Share

  371. CULLARO G
    Reply: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000434.
    >> Share


  372. May 2023 Hepatology Highlights.
    Hepatology. 2023;77:1461-1462.
    >> Share

    April 2023
  373. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
    Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
    >> Share


  374. July 2023 Hepatology Highlights.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000425.
    >> Share

  375. ADAMS LA, Schulte PJ, Allen AM
    Use of non-invasive scores to predict hepatic steatosis: Flaws and caveats.
    Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000419.
    >> Share

  376. HUNG MH, Chang CW, Wang KC, Chaisaingmongkol J, et al
    Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation.
    Hepatology. 2023 Apr 26. doi: 10.1097/HEP.0000000000000420.
    >> Share

  377. UFERE NN
    Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
    >> Share

  378. MALHI H, Shah V, Gores GJ
    Thematic reviews: the future of hepatology.
    Hepatology. 2023 Apr 19. doi: 10.1097/HEP.0000000000000409.
    >> Share

  379. TAPPER EB, Ospina E, Salim N, Chen X, et al
    Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
    Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
    >> Share

  380. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    >> Share

  381. MAESO-DIAZ R, Du K, Pan C, Guy CD, et al
    Targeting senescent hepatocytes using the THBD-PAR1 inhibitor Vorapaxar ameliorates NAFLD progression.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000401.
    >> Share

  382. JILG N, Baumert TF
    Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000400.
    >> Share

  383. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    >> Share

  384. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    >> Share

  385. RAABE J, Kaiser KM, ToVinh M, Finnemann C, et al
    Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis.
    Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000350.
    >> Share

  386. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    >> Share

  387. FRIEDMAN SL, Sanyal AJ
    The future of hepatology.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000389.
    >> Share

  388. ARUMUGAM S, Li B, Boodapati SLT, Nathanson MH, et al
    Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000388.
    >> Share

  389. TANG D, Kroemer G, Kang R
    Ferroptosis in hepatocellular carcinoma: from bench to bedside.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000390.
    >> Share


  390. June 2023 Hepatology Highlights.
    Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000391.
    >> Share

  391. TIAN Y, Jellinek MJ, Mehta K, Seok SM, et al
    Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000375.
    >> Share

  392. DESERT R, Chen W, Ge X, Viel R, et al
    Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000362.
    >> Share

  393. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Samala N, et al
    CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
    Hepatology. 2023;77:1241-1252.
    >> Share

  394. GUERRIERI F, Levrero M
    HBV, mitochondrial stress, and liver fibrosis: chicken or the egg.
    Hepatology. 2023;77:1088-1089.
    >> Share

  395. LIU Z, Tan M, Ding H
    Letter to the Editor: Contrast-enhanced CT and liver surface nodularity for the diagnosis of portosinusoidal vascular disorder: a case-control study.
    Hepatology. 2023;77:E71.
    >> Share

  396. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    >> Share

  397. SCHILSKY ML, Roberts EA, Bronstein JM, Dhawan A, et al
    A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
    Hepatology. 2023;77:1428-1455.
    >> Share

  398. YIP TC, Vilar-Gomez E, Petta S, Yilmaz Y, et al
    Geographical similarity and differences in the burden and genetic predisposition of NAFLD.
    Hepatology. 2023;77:1404-1427.
    >> Share

  399. LI HX, Xie ZQ, Yang ZM, Tang CX, et al
    Letter to the Editor: Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    Hepatology. 2023;77:E67-E68.
    >> Share

  400. AFONSO MB, Islam T, Magusto J, Amorim R, et al
    RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease.
    Hepatology. 2023;77:1319-1334.
    >> Share

  401. TORRES S, Ortiz C, Bachtler N, Gu W, et al
    Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
    Hepatology. 2023;77:1228-1240.
    >> Share

  402. KARDASHIAN A, Serper M, Terrault N, Nephew LD, et al
    Health disparities in chronic liver disease.
    Hepatology. 2023;77:1382-1403.
    >> Share

  403. LOPEZ-VICARIO C, Sebastian D, Casulleras M, Duran-Guell M, et al
    Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease.
    Hepatology. 2023;77:1303-1318.
    >> Share

  404. YANG F, Jiang S, Zheng Y
    Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?
    Hepatology. 2023;77:E62-E63.
    >> Share

  405. DEPRINCE A, Hennuyer N, Kooijman S, Pronk ACM, et al
    Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.
    Hepatology. 2023;77:1287-1302.
    >> Share

  406. JIANG M, Li F, Liu Y, Gu Z, et al
    Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.
    Hepatology. 2023;77:1164-1180.
    >> Share

  407. ZENG X, Liao G, Li S, Liu H, et al
    Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
    Hepatology. 2023;77:1122-1138.
    >> Share

  408. ZHOU Y, Jia K, Wang S, Li Z, et al
    Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7-acetylated and cytoplasm-translocated G protein GalphaS.
    Hepatology. 2023;77:1106-1121.
    >> Share

    March 2023
  409. ELHENCE H, Dodge JL, Farias AJ, Lee BP, et al
    Quantifying days at home in patients with cirrhosis: a national cohort study.
    Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000370.
    >> Share

  410. TRIPATHI D, Reiberger T
    Letter to the editor: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
    Hepatology. 2023 Mar 30. doi: 10.1097/HEP.0000000000000359.
    >> Share

  411. KWONG AJ, Zhang KY, Ebel N, Mannalithara A, et al
    MELD 3.0 for adolescent liver transplant candidates.
    Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000352.
    >> Share

  412. ELIAS G, Schonfeld M, Saleh S, Parrish M, et al
    Sepsis induced endothelial dysfunction drives acute-on-chronic liver failure via Angiopoietin-2-HGF-C/EBPbeta pathway.
    Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000354.
    >> Share

  413. HONG T, Xiong X, Chen Y, Wang Q, et al
    Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element binding protein-like 2.
    Hepatology. 2023 Mar 21. doi: 10.1097/HEP.0000000000000333.
    >> Share

  414. MAK LY, Yuen MF, Seto WK
    Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
    >> Share

  415. HUANG SC, Kao JH
    Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
    >> Share

  416. AHMED HS, Long MT
    Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000378.
    >> Share

  417. LI Z, Zhang L, Li J
    Letter to the Editor: the associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000377.
    >> Share

  418. ZHANG W, Wang MK, Yao D, Zhao HJ, et al
    Letter to the editor: hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000372.
    >> Share

  419. ROWE IA, Villanueva C, Shearer JE, Torres F, et al
    Quantifying the benefit of non-selective beta-blockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDESCI trial.
    Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000342.
    >> Share

  420. ALLAIRE M, Thabut D
    Reply: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
    Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000358.
    >> Share


  421. May 2023 Hepatology Highlights.
    Hepatology. 2023 Mar 8. doi: 10.1097/HEP.0000000000000355.
    >> Share

  422. SMITH ML, Wade JB, Wolstenholme J, Bajaj JS, et al
    Gut microbiome-brain-cirrhosis axis.
    Hepatology. 2023 Mar 6. doi: 10.1097/HEP.0000000000000344.
    >> Share

  423. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
    Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study.
    Hepatology. 2023;77:834-850.
    >> Share

  424. VAN KLEEF LA, de Knegt RJ
    Modifiable risk factors for fatty liver disease: Time to act.
    Hepatology. 2023;77:712-714.
    >> Share

  425. LUO W, Gu Y, Zhang T
    Letter to the editor: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage HCC.
    Hepatology. 2023;77:E51-E52.
    >> Share

  426. SUN Y, Zhang J, Wang H, Wang W, et al
    Letter to the editor: Fatty liver and mortality in populations who are elderly.
    Hepatology. 2023;77:E47-E48.
    >> Share

  427. TARLOW BD, Kim WR, Mannalithara A, Kwo PY, et al
    Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
    Hepatology. 2023;77:851-861.
    >> Share

  428. JIANG ST, Xu YY, Lu X
    Letter to the editor: Focus on metabolic dysfunction-associated fatty liver disease, even if patients have a history of excessive alcohol consumption.
    Hepatology. 2023;77:E43-E44.
    >> Share

  429. UDOMPAP P, Therneau TM, Canning RE, Benson JT, et al
    Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
    Hepatology. 2023;77:931-941.
    >> Share

  430. XIE J, Huang H, Liu Z, Li Y, et al
    The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study.
    Hepatology. 2023;77:949-964.
    >> Share

  431. FONTANA RJ, Liou I, Reuben A, Suzuki A, et al
    AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.
    Hepatology. 2023;77:1036-1065.
    >> Share

  432. NING C, Jiang ST, Sang XT
    Letter to the editor: Reflection on the no-association between the presence of fatty liver disease and mortality in the elderly.
    Hepatology. 2023;77:E39-E40.
    >> Share

  433. CANIVET CM, Costentin C, Irvine KM, Delamarre A, et al
    Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Hepatology. 2023;77:920-930.
    >> Share

  434. VAN KLEEF LA, de Knegt RJ, Brouwer WP
    Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    Hepatology. 2023;77:942-948.
    >> Share

  435. LI S, Zhou B, Xue M, Zhu J, et al
    Macrophage-specific FGF12 promotes liver fibrosis progression in mice.
    Hepatology. 2023;77:816-833.
    >> Share

  436. CRESPO M, Nikolic I, Mora A, Rodriguez E, et al
    Myeloid p38 activation maintains macrophage-liver crosstalk and BAT thermogenesis through IL-12-FGF21 axis.
    Hepatology. 2023;77:874-887.
    >> Share

  437. CHAN CY, Yuen VW, Chiu DK, Goh CC, et al
    Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
    Hepatology. 2023;77:729-744.
    >> Share

    February 2023
  438. ZANETTO A, Campello E, Senzolo M, Simioni P, et al
    The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
    Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000349.
    >> Share

  439. TAPPER EB, Serper M, Goldberg D
    Implementing pragmatic clinical trials in hepatology.
    Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000345.
    >> Share

  440. DU K, Maeso-Diaz R, Oh SH, Wang E, et al
    Targeting YAP-mediated hepatic stellate cell death susceptibility and senescence for treatment of liver fibrosis.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000326.
    >> Share

  441. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    >> Share

  442. NICOARA-FARCAU O, Lozano JJ, Alonso C, Sidorova J, et al
    Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis.
    Hepatology. 2023 Feb 23. doi: 10.1097/HEP.0000000000000316.
    >> Share

  443. GAWRIEH S, Lake JE, Debroy P, Sjoquist JA, et al
    Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
    Hepatology. 2023 Feb 22. doi: 10.1097/HEP.0000000000000313.
    >> Share

  444. CHENG L, Deepak RNVK, Wang G, Meng Z, et al
    Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKalpha mediating lipid metabolism and tumorigenesis.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000314.
    >> Share


  445. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
    >> Share

  446. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    >> Share

  447. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    >> Share

  448. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    >> Share

  449. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    >> Share

  450. HU Y, Li Z, Jiang Y, Wang X, et al
    Letter to the Editor: More efforts for the meta-analysis of the association between hepatic steatosis and HBV-related HCC.
    Hepatology. 2023 Feb 9. doi: 10.1097/HEP.0000000000000332.
    >> Share


  451. April 2023 Hepatology Highlights.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000325.
    >> Share

  452. SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
    Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
    >> Share

  453. ROWE IA, Allen AM
    Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
    Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000327.
    >> Share

  454. PATOULIAS D
    Letter to the Editor: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
    Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000311.
    >> Share

  455. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
    Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
    Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000312.
    >> Share


  456. February 2023 Hepatology Highlights.
    Hepatology. 2023;77:339-340.
    >> Share

  457. WANG M, Sarkar M, Mehta N
    Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression.
    Hepatology. 2023;77:341-343.
    >> Share

  458. LARRUE H, Bureau C
    Transjugular intrahepatic portosystemic shunt in portal hypertension: How to go further while staying on track?
    Hepatology. 2023;77:344-346.
    >> Share

  459. LI J, Nguyen MH
    Letter to the editor: Screening for fatty liver disease and fibrosis in the elderly population: A call for action.
    Hepatology. 2023;77:E28-E29.
    >> Share

  460. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    >> Share

  461. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.
    >> Share

  462. SHAN J, Megarbane A, Chouchane A, Karthik D, et al
    Genetic predisposition to porto-sinusoidal vascular disorder: A functional genomic-based, multigenerational family study.
    Hepatology. 2023;77:501-511.
    >> Share

  463. HAGSTROM H, Shang Y
    Less is more? Screening for steatosis in older populations.
    Hepatology. 2023;77:350-351.
    >> Share

  464. LIN H, Yip TC, Zhang X, Li G, et al
    Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease.
    Hepatology. 2023;77:573-584.
    >> Share

  465. MONDIA N, Singh SP, Mishra AK
    Letter to the editor: Risk factors of NAFLD in preterm and low birthweight. More questions than answers!
    Hepatology. 2023;77:E17.
    >> Share

  466. VAN KLEEF LA, Sonneveld MJ, Kavousi M, Ikram MA, et al
    Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study.
    Hepatology. 2023;77:585-593.
    >> Share

  467. XU L, Yang Y, Jiang J, Wen Y, et al
    Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production.
    Hepatology. 2023;77:456-465.
    >> Share

  468. INDIRA CHANDRAN V, Wernberg CW, Lauridsen MM, Skytthe MK, et al
    Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness.
    Hepatology. 2023;77:558-572.
    >> Share

  469. AJOOLABADY A, Kaplowitz N, Lebeaupin C, Kroemer G, et al
    Endoplasmic reticulum stress in liver diseases.
    Hepatology. 2023;77:619-639.
    >> Share

    January 2023
  470. ADEJUMO AC, Yakovchenko V, Morgan TR, Spoutz P, et al
    The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 veterans.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000306.
    >> Share

  471. LUO J, Gong L, Yang Y, Zhang Y, et al
    Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in hepatocellular carcinoma.
    Hepatology. 2023 Jan 24. doi: 10.1097/HEP.0000000000000299.
    >> Share

  472. AHMED HS, Wang N, Carr JJ, Ding J, et al
    The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multi-cohort study.
    Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000286.
    >> Share

  473. HUANG DQ, Tamaki N, Lee HW, Park SY, et al
    Outcome of untreated low-level viremia vs. antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000037.
    >> Share

  474. CUNNINGHAM M, Gupta R, Butler M
    Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
    >> Share

  475. EL HAJRA I, Sanduzzi-Zamparelli M, Sapena V, Munoz-Martinez S, et al
    Outcome of patients with hepatocellular carcinoma and liver dysfunction under Immunotherapy: a systematic review and meta-analysis.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000030.
    >> Share


  476. March 2023 Hepatology Highlights.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000289.
    >> Share

  477. ALLAIRE M, Thabut D
    Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000291.
    >> Share

  478. LIU F, Liao Z, Qin L, Zhang Z, et al
    Targeting VPS72 inhibits ACTL6A/MYC axis activity in hepatocellular carcinoma progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000268.
    >> Share

  479. CASTERA L, Cusi K
    Diabetes and cirrhosis: Current concepts on diagnosis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.
    >> Share

  480. YU H, Zhou L, Loong JH, Lam KH, et al
    SERPINA12 promotes the tumorigenic capacity of hepatocellular carcinoma stem cells through hyperactivation of AKT/ beta-catenin signaling.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000269.
    >> Share

  481. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    >> Share

  482. GONG L, Wei F, Gonzalez FJ, Li G, et al
    Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000182.
    >> Share

  483. BEHRENDT P, Gouttenoire J
    Editorial in Hepatology Urine: A place where HEV cannot hide!
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000017.
    >> Share

  484. HAO L, Zhong W, Woo J, Wei X, et al
    Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining A. muciniphila in alcoholic steatohepatitis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000019.
    >> Share

  485. YOUNOSSI Z, Golabi P, Paik J, Henry A, et al
    The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000004.
    >> Share

  486. LV Y, Han G
    Reply to HEP-22-1980 Embolization of large spontaneous shunt for the prevention of hepatic encephalopathy after TIPS: more questions than answers.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000010.
    >> Share

  487. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    >> Share

  488. LO GH
    Is embolization of large spontaneous shunt effective in the prevention of hepatic encephalopathy after TIPS?
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000007.
    >> Share

  489. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    >> Share

  490. FU S, Liu M, Zhu C, Zhang H, et al
    Regulatory MAIT cells controlled by beta1 adrenergic receptor signaling contribute to hepatocellular carcinoma progression.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000014.
    >> Share

  491. WANG S, Wang R, Xu N, Wei X, et al
    SULT2B1-CS-DOCK2 axis regulates effector T cell exhaustion in hepatocellular carcinoma microenvironment.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000025.
    >> Share

  492. KODAMA T, Takehara T
    Is it a prime time for germline genetic testing for hepatocellular carcinoma?
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000033.
    >> Share

  493. BHALA N, Ferguson JW, Rajoriya N, Newsome PN, et al
    Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000011.
    >> Share

  494. WANG CC, Kao JH
    Letter to the Editor Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000009.
    >> Share

  495. CABIBBO G, Celsa C, Alimenti E, Iavarone M, et al
    Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced hepatocellular carcinoma: the dark side of the moon.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000205.
    >> Share

  496. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    >> Share

  497. FENG Y, Peng B, Li Y, Sun L, et al
    Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000209.
    >> Share

  498. KHORASANI S, Boike J, Duarte-Rojo A
    Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000235.
    >> Share

  499. MA F, Liu Y, Hu Z, Xue Y, et al
    Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000042.
    >> Share

  500. CHUNG HH
    Letter to the Editor: The pathological impact of PAR2 on hepatic insulin resistance.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000284.
    >> Share

  501. CHANG D, Truong E, Noureddin M
    Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: Accuracy and routine variables are the success keys.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000211.
    >> Share

  502. TANTAI X, Wang J, Dai S
    Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000271.
    >> Share

  503. DUAN S, Qin N, Pi J, Sun P, et al
    Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000185.
    >> Share

  504. SHARPTON SR, Loomba R
    Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000278.
    >> Share

  505. KARDASHIAN A, Kushner T, Au JS, Flemming JA, et al
    The key role of hepatology providers in optimizing reproductive care in patients with liver disease: a call to action.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000275.
    >> Share

  506. CAO J, Bai DS
    Letter to the editor: Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
    Hepatology. 2023;77:E11.
    >> Share

  507. SEMMLER G, Thorhauge KH, Reiberger T, Thiele M, et al
    Letter to the editor: Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
    Hepatology. 2023;77:E1-E2.
    >> Share

  508. WADHWANI SI, Lai JC
    The digital determinants of liver disease.
    Hepatology. 2023;77:13-14.
    >> Share

  509. LINDBLAD KE, Lujambio A
    Imaging for better responses to immunotherapy in hepatocellular carcinoma.
    Hepatology. 2023;77:6-9.
    >> Share

  510. HENSON JB, Wegermann K, Patel YA, Wilder JM, et al
    Access to technology to support telehealth in areas without specialty care for liver disease.
    Hepatology. 2023;77:176-185.
    >> Share

  511. GIDENER T, Dierkhising RA, Mara KC, Therneau TM, et al
    Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
    Hepatology. 2023;77:268-274.
    >> Share

  512. ZHANG L, Guo GL
    Gut-specific inhibition of PPARalpha as a novel approach of NAFLD treatment.
    Hepatology. 2023;77:15-17.
    >> Share

  513. GOYAL NP, Rosenthal SB, Nasamran C, Behling CA, et al
    Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children.
    Hepatology. 2023;77:197-212.
    >> Share

  514. HAGSTROM H
    A new model for estimation of significant fibrosis in primary care. SAFE to use?
    Hepatology. 2023;77:18-19.
    >> Share

  515. SRIPONGPUN P, Kim WR, Mannalithara A, Charu V, et al
    The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
    Hepatology. 2023;77:256-267.
    >> Share

  516. REN Z, Simons PIHG, Wesselius A, Stehouwer CDA, et al
    Relationship between NAFLD and coronary artery disease: A Mendelian randomization study.
    Hepatology. 2023;77:230-238.
    >> Share

  517. KOMUTA M, Ueno A, Sakamoto M
    The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer.
    Hepatology. 2023;77:10-12.
    >> Share


  518. January 2023 Hepatology Highlights.
    Hepatology. 2023;77:1-2.
    >> Share


  519. January 2023 Hepatology Highlights.
    Hepatology. 2023;77:1-2.
    >> Share


  520. January 2023 Hepatology Highlights.
    Hepatology. 2023;77:1-2.
    >> Share

    December 2022
  521. ZHANG J, Xu Y, Lu X, Zhao H, et al
    Letter to the editor: NAFLD and sarcopenia: Association or causation?
    Hepatology. 2022;76:E119-E120.
    >> Share

  522. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: Complications following SARS-CoV-2 infection in patients with chronic liver disease.
    Hepatology. 2022;76:E116.
    >> Share

  523. XUN Z, Zhao H
    Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?
    Hepatology. 2022;76:E127-E128.
    >> Share

  524. SHEARER AM, Wang Y, Fletcher EK, Rana R, et al
    PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.
    Hepatology. 2022;76:1778-1793.
    >> Share

  525. SINN DH, Kang D, Kang M, Guallar E, et al
    Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study.
    Hepatology. 2022;76:1746-1754.
    >> Share

  526. KIM Y, Chang Y, Ryu S, Wild SH, et al
    NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
    Hepatology. 2022;76:1755-1765.
    >> Share

  527. SHARMA D, Ben Yakov G, Kapuria D, Viana Rodriguez G, et al
    Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity.
    Hepatology. 2022;76:1845-1861.
    >> Share

  528. RATZIU V, Anstee QM, Wong VW, Schattenberg JM, et al
    An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.
    Hepatology. 2022;76:1766-1777.
    >> Share

  529. HUANG M, Jiao J, Cai H, Zhang Y, et al
    C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner.
    Hepatology. 2022;76:1706-1722.
    >> Share

  530. FENG R, Kan K, Sticht C, Li Y, et al
    A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions.
    Hepatology. 2022;76:1673-1689.
    >> Share

  531. HONG F, Lin CY, Yan J, Dong Y, et al
    Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53.
    Hepatology. 2022;76:1587-1601.
    >> Share

  532. ASIF B, Ortiz V, Conboy CB, Diaz LA, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1555-1556.
    >> Share

    November 2022
  533. CHUNG HH
    Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation.
    Hepatology. 2022;76:E106-E107.
    >> Share

  534. ATTIA D, Gomaa A, Abdel Alem S
    Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD.
    Hepatology. 2022;76:E100.
    >> Share

  535. VAN KLEEF LA, de Knegt RJ
    The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?
    Hepatology. 2022;76:1243-1245.
    >> Share

  536. AMADOU C, Nabi O, Serfaty L, Lacombe K, et al
    Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2022;76:1438-1451.
    >> Share

  537. SHANG Y, Nasr P, Widman L, Hagstrom H, et al
    Risk of cardiovascular disease and loss in life expectancy in NAFLD.
    Hepatology. 2022;76:1495-1505.
    >> Share

  538. OLIVEIRA CP
    Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
    Hepatology. 2022;76:1246-1247.
    >> Share

  539. YOUNOSSI ZM, Paik JM, Al Shabeeb R, Golabi P, et al
    Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Hepatology. 2022;76:1423-1437.
    >> Share

  540. RIMOLA J, Sapena V, Brancatelli G, Darnell A, et al
    Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.
    Hepatology. 2022;76:1318-1328.
    >> Share

  541. VILAR-GOMEZ E, Pirola CJ, Sookoian S, Wilson LA, et al
    PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.
    Hepatology. 2022;76:1482-1494.
    >> Share

  542. ZHANG X, Wong GL, Yip TC, Cheung JTK, et al
    Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
    Hepatology. 2022;76:1409-1422.
    >> Share

  543. LEI L, Bruneau A, El Mourabit H, Guegan J, et al
    Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
    Hepatology. 2022;76:1360-1375.
    >> Share

  544. TOMLINSON JL, Penrice DD, Ramkissoon R, Udompap P, et al
    Hepatology highlights.
    Hepatology. 2022;76:1231-1232.
    >> Share

  545. FOUAD Y, Abdel Dayem WA, Mehrez M
    Letter to the editor: Apples should be compared with apples.
    Hepatology. 2022;76:E101.
    >> Share

    October 2022

  546. Erratum for Jiang L, et al. calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway.
    Hepatology. 2022 Oct 26. doi: 10.1002/hep.32796.
    >> Share

  547. LAM YK, Yu J, Huang H, Ding X, et al
    TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
    Hepatology. 2022 Oct 11. doi: 10.1002/hep.32802.
    >> Share

  548. RAHAL HK, Tabibian JH, Issaka RB, Quezada S, et al
    Diversity, equity, and inclusion in gastroenterology and hepatology: A survey of where we stand.
    Hepatology. 2022 Oct 11. doi: 10.1002/hep.32757.
    >> Share

  549. WU T, Povero D, Parthasarathy G, Idalsoaga F, et al
    Hepatology highlights.
    Hepatology. 2022;76:901-902.
    >> Share

  550. SUCHMAN K, Da BL
    Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.
    Hepatology. 2022;76:E78-E79.
    >> Share

  551. DEVARBHAVI H, Kurien SS
    Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.
    Hepatology. 2022;76:E71-E72.
    >> Share

  552. BARROW F, Revelo XS
    The B side of B cells in NAFLD.
    Hepatology. 2022;76:914-916.
    >> Share

  553. PAI RK, Jairath V, Hogan M, Zou G, et al
    Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
    Hepatology. 2022;76:1150-1163.
    >> Share

  554. LASCHTOWITZ A, Tacke F
    Many roads lead to Rome: The FGF4-AMP-activated protein kinase-Caspase 6 signal axis in NAFLD and NASH.
    Hepatology. 2022;76:911-913.
    >> Share

  555. MARTINEZ-ARRANZ I, Bruzzone C, Noureddin M, Gil-Redondo R, et al
    Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
    Hepatology. 2022;76:1121-1134.
    >> Share

  556. KARL M, Hasselwander S, Zhou Y, Reifenberg G, et al
    Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.
    Hepatology. 2022;76:1135-1149.
    >> Share

  557. SONG L, Wang L, Hou Y, Zhou J, et al
    FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
    Hepatology. 2022;76:1105-1120.
    >> Share

  558. WANG H, Zhang B, Li R, Chen J, et al
    KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration.
    Hepatology. 2022;76:967-981.
    >> Share

  559. BAPTISSART M, Bradish CM, Jones BS, Walsh E, et al
    Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome.
    Hepatology. 2022;76:1090-1104.
    >> Share

  560. WANG H, Zhou Y, Xu H, Wang X, et al
    Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
    Hepatology. 2022;76:951-966.
    >> Share

  561. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    >> Share

    September 2022
  562. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
    Reply to the Letter to the Editor: "Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?"
    Hepatology. 2022 Sep 30. doi: 10.1002/hep.32813.
    >> Share

  563. VAZ K, Little R, Majeed A, Roberts S, et al
    Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?
    Hepatology. 2022 Sep 28. doi: 10.1002/hep.32811.
    >> Share

  564. ALLEGRETTI AS
    NGAL in AKI and cirrhosis - ready for prime time?
    Hepatology. 2022 Sep 28. doi: 10.1002/hep.32807.
    >> Share

  565. YIP TC, Wong VW, Wong GL
    Does hepatic steatosis impact chronic hepatitis B?
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
    >> Share

  566. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    >> Share

  567. GAMBINO C, Piano S, Stenico M, Tonon M, et al
    Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
    Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
    >> Share

  568. MANNA D, Reghupaty SC, Camarena MDC, Mendoza RG, et al
    Melanoma Differentiation Associated Gene-9/Syndecan Binding Protein (MDA-9/SDCBP) Promotes Hepatocellular Carcinoma (HCC).
    Hepatology. 2022 Sep 19. doi: 10.1002/hep.32797.
    >> Share

  569. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
    >> Share

  570. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    >> Share

  571. CHEN YT, Su YC, Or YE, Cheng CF, et al
    CD8(+) T cell memory is sustained in mice by hepatic stellate cells.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32788.
    >> Share

  572. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
    Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
    >> Share

  573. LIU Y, Zhang J, Xu Y, Lu X, et al
    Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
    Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.
    >> Share

  574. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
    Reply to the Letter to the Editor: "Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients".
    Hepatology. 2022 Sep 13. doi: 10.1002/hep.32784.
    >> Share

  575. LESLIE J, Hunter JE, Collins A, Rushton A, et al
    c-Rel dependant Chk2 signalling regulates the DNA damage response limiting hepatocarcinogenesis.
    Hepatology. 2022 Sep 11. doi: 10.1002/hep.32781.
    >> Share

  576. LEE YT, Fujiwara N, Yang JD, Hoshida Y, et al
    Risk stratification and early detection biomarkers for precision hepatocellular carcinoma screening.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32779.
    >> Share

  577. DELLINGER RW, Holmes HE, Hu-Seliger T, Butt RW, et al
    NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32778.
    >> Share


  578. Retracted: Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
    Hepatology. 2022 Sep 8. doi: 10.1002/hep.32736.
    >> Share

  579. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
    Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
    Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
    >> Share

  580. DUAN Z
    Postvaccination COVID-19 related mortality in patients with cirrhosis:who is the culprit?
    Hepatology. 2022 Sep 5. doi: 10.1002/hep.32750.
    >> Share

  581. HUANG H, Wu L, Lu L, Zhang Z, et al
    Single-cell Transcriptomics Uncovers Cellular Architecture and Developmental Trajectories in Hepatoblastoma.
    Hepatology. 2022 Sep 4. doi: 10.1002/hep.32775.
    >> Share

  582. KNORR J, Kaufmann B, Inzaugarat ME, Holtmann TM, et al
    Interleukin-18 signaling promotes activation of hepatic stellate cells in murine liver fibrosis.
    Hepatology. 2022 Sep 4. doi: 10.1002/hep.32776.
    >> Share

  583. VAN ZWOL W, Rimbert A, Wolters JC, Smit M, et al
    Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion.
    Hepatology. 2022 Sep 2. doi: 10.1002/hep.32709.
    >> Share

  584. JENSEN DM, Rzepczynski A, Jensen EE, Reau N, et al
    The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.
    Hepatology. 2022;76:854-859.
    >> Share

  585. CULLARO G, Verna EC, McCulloch CE, Lai JC, et al
    Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types.
    Hepatology. 2022;76:689-699.
    >> Share

  586. ZABALETA N, Torella L, Weber ND, Gonzalez-Aseguinolaza G, et al
    mRNA and gene editing: Late breaking therapies in liver diseases.
    Hepatology. 2022;76:869-887.
    >> Share

  587. HARRIS EN
    Will inhibition of cellular crosstalk resolve liver fibrosis?
    Hepatology. 2022;76:558-560.
    >> Share

  588. ZHENG M, Allington G, Vilarinho S
    Genomic medicine for liver disease.
    Hepatology. 2022;76:860-868.
    >> Share

  589. CALCAGNO DM, Chu A, Gaul S, Taghdiri N, et al
    NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH.
    Hepatology. 2022;76:727-741.
    >> Share

  590. LIN Y, Dong MQ, Liu ZM, Xu M, et al
    A strategy of vascular-targeted therapy for liver fibrosis.
    Hepatology. 2022;76:660-675.
    >> Share

  591. ALVA-RUIZ R, Ahn JC, Udompap P, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;76:539-540.
    >> Share

    August 2022
  592. QUECK A, Praktiknjo M, Jansen C, Trebicka J, et al
    Response to the letter to the editor: "Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS".
    Hepatology. 2022 Aug 25. doi: 10.1002/hep.32754.
    >> Share

  593. LUO W, Wang Y, Li Y, Zhang T, et al
    Letter to the editor: Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
    Hepatology. 2022 Aug 25. doi: 10.1002/hep.32755.
    >> Share

  594. HU S, Monga SP
    Response to the "Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin".
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32694.
    >> Share

  595. JOHN BV, Dahman B
    COVID-19 related mortality in Cirrhosis is not associated with Proton Pump Inhibitor Exposure.
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32748.
    >> Share

  596. LO GH
    Could COVID-19 vaccination reduce post-infection mortality in most cirrhotic patients ?
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32751.
    >> Share

  597. JOHN BV, Dahman B
    COVID-19 Vaccination and mortality in Decompensated Cirrhosis.
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32749.
    >> Share

  598. LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
    Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
    >> Share

  599. DONNE R, Lujambio A
    The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32740.
    >> Share

  600. ZONG C, Meng Y, Ye F, Yang X, et al
    AIF1(+) CSF1R(+) MSCs, induced by TNF-alpha, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32738.
    >> Share

  601. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    >> Share

  602. DEMORY A, Peron JM, Calderaro J, Selves J, et al
    Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
    Hepatology. 2022 Aug 18. doi: 10.1002/hep.32734.
    >> Share

  603. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    >> Share

  604. GOUON-EVANS V, Fiorotto R
    Fibroblasts to hepatocytes: a non-stop flight into cell therapy for liver diseases?
    Hepatology. 2022 Aug 11. doi: 10.1002/hep.32725.
    >> Share

  605. LIU T, Wang Q, Zhou L, Zhang P, et al
    Intrahepatic paracrine signaling by CLCF1 ameliorates diet-induced NASH in mice.
    Hepatology. 2022 Aug 11. doi: 10.1002/hep.32719.
    >> Share

  606. WU Y, Hao X, Wei H, Sun R, et al
    TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
    Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
    >> Share

  607. RODRIGUEZ TC, Kwan S, Smith JL, Dadafarin S, et al
    Multi-omics characterization of mouse hepatoblastoma identifies novel YAP1 target genes.
    Hepatology. 2022 Aug 6. doi: 10.1002/hep.32713.
    >> Share

  608. LIU X, Wang K, Wang L, Kong L, et al
    Hepatocyte Ltb4r1 promotes NAFLD development in obesity.
    Hepatology. 2022 Aug 5. doi: 10.1002/hep.32708.
    >> Share

  609. LIANG B, Wang H, Qiao Y, Wang X, et al
    Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation driven hepatocarcinogenesis.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32693.
    >> Share

  610. VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
    Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
    >> Share

  611. PENUELAS-HARO I, Espinosa-Sotelo R, Crosas-Molist E, Herranz-Iturbide M, et al
    The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing hepatocellular carcinoma progression.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32702.
    >> Share

  612. NING C, Zhang XM, Sang XT, Zhao HT, et al
    Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin.
    Hepatology. 2022 Aug 2. doi: 10.1002/hep.32695.
    >> Share

  613. PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
    Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
    Hepatology. 2022;76:E51-E52.
    >> Share

  614. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Discussion on application scenario of cell-free DNA fragmentomics in primary liver cancer.
    Hepatology. 2022;76:E44.
    >> Share

  615. JINDAL A
    Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
    Hepatology. 2022;76:E42.
    >> Share

  616. GUIDOTTI LG, La Vecchia C, Colombo M
    Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
    Hepatology. 2022;76:300-302.
    >> Share

  617. PANIGRAHI MK, Anirvan P
    Letter to the editor: Using angiotensin-converting enzyme inhibitors to prevent liver-related events in NAFLD-Revisiting the renin-angiotensin-aldosterone system pathways.
    Hepatology. 2022;76:E32-E33.
    >> Share

  618. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    >> Share

  619. VOS MB, Van Natta ML, Blondet NM, Dasarathy S, et al
    Randomized placebo-controlled trial of losartan for pediatric NAFLD.
    Hepatology. 2022;76:429-444.
    >> Share

  620. AGOPIAN VG, Yang JD, Zhu Y, You S, et al
    Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?
    Hepatology. 2022;76:289-291.
    >> Share

  621. MAO Y, Han CY, Hao L, Lee Y, et al
    p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
    Hepatology. 2022;76:345-356.
    >> Share

  622. VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
    Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
    Hepatology. 2022;76:418-428.
    >> Share

  623. PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
    Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
    Hepatology. 2022;76:456-468.
    >> Share

  624. GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
    Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
    Hepatology. 2022;76:372-386.
    >> Share

  625. SOFTIC S, Kohli R
    Pediatric NASH therapies: A speedbump on the road to success.
    Hepatology. 2022;76:292-294.
    >> Share

  626. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    >> Share

  627. ZHANG X, Wong GL, Yip TC, Tse YK, et al
    Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
    Hepatology. 2022;76:469-482.
    >> Share

  628. HAN B, Francipane MG, Cheikhi A, Johnson J, et al
    Fat-associated lymphoid clusters as expandable niches for ectopic liver development.
    Hepatology. 2022;76:357-371.
    >> Share

  629. XIONG H, Zhang C, Han L, Xu T, et al
    Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity.
    Hepatology. 2022;76:387-403.
    >> Share

    July 2022
  630. SUN N, Zhang C, Lee YT, Tran BV, et al
    HCC EV ECG Score: An Extracellular Vesicle-based Protein Assay for Detection of Early-Stage Hepatocellular Carcinoma.
    Hepatology. 2022 Jul 31. doi: 10.1002/hep.32692.
    >> Share

  631. BAI Y, Yang Z, Xu X, Ding W, et al
    Direct chemical induction of hepatocyte-like cells with capacity for liver repopulation.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32686.
    >> Share

  632. QUECK A, Schwierz L, Gu W, Ferstl PG, et al
    Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
    Hepatology. 2022 Jul 23. doi: 10.1002/hep.32676.
    >> Share

  633. HU S, Cao C, Poddar M, Delgado E, et al
    Hepatocyte beta-Catenin Loss is Compensated by Insulin-mTORC1 Activation to Promote Liver Regeneration.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32680.
    >> Share

  634. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
    >> Share

  635. LIU X, Tan S, Liu H, Jiang J, et al
    Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
    Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
    >> Share

  636. LAI SW
    Aspirin use and the risk of hepatocellular carcinoma.
    Hepatology. 2022 Jul 17. doi: 10.1002/hep.32674.
    >> Share

  637. ZHONG D, Cai J, Hu C, Chen J, et al
    Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32671.
    >> Share

  638. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
    >> Share

  639. POZO-MORALES M, Garteizgogeascoa I, Perazzolo C, So J, et al
    In vivo imaging of calcium dynamics in zebrafish hepatocytes.
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32663.
    >> Share

  640. YANG F, Jiang ST, Lu X, Xu Y, et al
    Letter to the editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
    Hepatology. 2022 Jul 11. doi: 10.1002/hep.32659.
    >> Share

  641. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    >> Share

  642. CHANG D, Truong E, Mena EA, Pacheco F, et al
    Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
    Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
    >> Share

  643. ZHANG Y, Ye S, Lu W, Zhong J, et al
    RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
    Hepatology. 2022 Jul 7. doi: 10.1002/hep.32651.
    >> Share

  644. KOVALIC AJ, Lee TP, Da BL
    Letter to the editor: L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
    Hepatology. 2022 Jul 5. doi: 10.1002/hep.32643.
    >> Share

  645. RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
    Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
    Hepatology. 2022;76:E23.
    >> Share

  646. DANAN G, Teschke R
    Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
    Hepatology. 2022;76:E27.
    >> Share

  647. RASCHI E, Caraceni P
    Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
    Hepatology. 2022;76:E25-E26.
    >> Share

  648. KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
    Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
    Hepatology. 2022;76:E7-E8.
    >> Share

  649. TAO X, Zhao Y, Chen L, Zeng M, et al
    Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;76:E13-E14.
    >> Share

  650. KAPPUS MR, Patel YA, Duarte-Rojo A
    Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
    Hepatology. 2022;76:12-14.
    >> Share

  651. PISCAGLIA F
    Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
    Hepatology. 2022;76:6-8.
    >> Share

  652. HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
    A revised electronic version of RUCAM for the diagnosis of DILI.
    Hepatology. 2022;76:18-31.
    >> Share

  653. SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
    Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;76:251-274.
    >> Share

  654. LEWIS JH
    Digitizing DILI: Who can? RUCAM? RECAM?
    Hepatology. 2022;76:3-5.
    >> Share

  655. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
    Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022;76:186-195.
    >> Share

  656. STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
    NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
    Hepatology. 2022;76:172-185.
    >> Share

  657. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
    Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
    Hepatology. 2022;76:275-285.
    >> Share

  658. POVERO D, Ahn JC, Arnold J, Udompap P, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1-2.
    >> Share

  659. FAN Y, Jiang ST, Yong-Chang Z
    Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32644.
    >> Share

  660. SCHMID CD, Olsavszky V, Reinhart M, Weyer V, et al
    ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver.
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32641.
    >> Share

    June 2022
  661. TRAN NH, Munoz S, Thompson S, Hallemeier CL, et al
    Hepatocellular Carcinoma Down-Staging for Liver Transplantation in the Era of Systemic Combined Therapy with Anti-VEGF/TKI and Immunotherapy.
    Hepatology. 2022 Jun 28. doi: 10.1002/hep.32613.
    >> Share

  662. MALHI H, Gores GJ
    What is Hepatology looking for Version 2.0?
    Hepatology. 2022 Jun 26. doi: 10.1002/hep.32637.
    >> Share

  663. JIANG ST, Xu YY, Lu X
    Letter to the Editor: Using intratumoral steatosis to predict the efficacy of combination therapy in nonviral hepatocellular carcinoma.
    Hepatology. 2022 Jun 25. doi: 10.1002/hep.32628.
    >> Share

  664. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    >> Share

  665. YUAN T, Zhou T, Qian M, Du J, et al
    SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
    >> Share

  666. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
    Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
    Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
    >> Share

  667. LI B, Yu D
    Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
    Hepatology. 2022 Jun 15. doi: 10.1002/hep.32616.
    >> Share

  668. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    >> Share

  669. LIAO J, Yi Y, Yue X, Wu X, et al
    METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32615.
    >> Share

  670. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    >> Share

  671. AHMAD A
    Letter to the Editor: The Precise Relationship Between MELD and Survival Without a Liver Transplant.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32602.
    >> Share

  672. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    >> Share

  673. HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
    Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
    Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
    >> Share

  674. DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
    The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
    Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
    >> Share

  675. TESTINO G
    Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification.
    Hepatology. 2022;75:1662-1663.
    >> Share

  676. JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
    Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
    Hepatology. 2022;75:1480-1490.
    >> Share

  677. SANDAHL TD, Gormsen LC, Kjaergaard K, Vendelbo MH, et al
    The pathophysiology of Wilson's disease visualized: A human (64) Cu PET study.
    Hepatology. 2022;75:1461-1470.
    >> Share

  678. QIAN Q, Li Y, Fu J, Leng D, et al
    Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
    Hepatology. 2022;75:1507-1522.
    >> Share

  679. VILAR-GOMEZ E, Nephew LD, Vuppalanchi R, Gawrieh S, et al
    High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
    Hepatology. 2022;75:1491-1506.
    >> Share

  680. PSARAKI A, Ntari L, Karakostas C, Korrou-Karava D, et al
    Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.
    Hepatology. 2022;75:1590-1603.
    >> Share

  681. ALVA-RUIZ R, Wu T, Idalsoaga F, Ramkissoon R, et al
    Hepatology highlights.
    Hepatology. 2022;75:1363-1364.
    >> Share

    May 2022
  682. ZHANG JW, Fang J, Xun Z, Xu Y, et al
    Letter to the Editor: Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in the Real World.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32588.
    >> Share

  683. KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
    Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
    >> Share

  684. JALAN-SAKRIKAR N, Brevini T, Huebert RC, Sampaziotis F, et al
    Organoids and Regenerative Hepatology.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32583.
    >> Share

  685. LI L, Zhang Y, Zhou Y, Hu H, et al
    Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32584.
    >> Share

  686. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    >> Share

  687. XU W, Cui C, Cui C, Chen Z, et al
    Hepatocellular Cystathionine gamma lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32577.
    >> Share

  688. PILLING LC, Atkins JL, Melzer D
    Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
    >> Share

  689. MURAI H, Kodama T, Maesaka K, Tange S, et al
    Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32573.
    >> Share

  690. BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
    Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
    >> Share

  691. KIM KE, Lee J, Shin HJ, Jeong EA, et al
    Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32569.
    >> Share

  692. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    >> Share

  693. MEHTA S, Asrani SK
    The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
    Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
    >> Share

  694. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    >> Share

  695. GULATI P, Taneja S, Duseja A, Singh V, et al
    Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
    Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
    >> Share

  696. LIU JJ, Xin B, Du L, Chen L, et al
    Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
    >> Share

  697. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
    Fontan-associated liver disease.
    Hepatology. 2022;75:1300-1321.
    >> Share

  698. LEE CH, Lui DTW, Lam KSL
    Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
    Hepatology. 2022;75:1340.
    >> Share

  699. CHUNG HH
    Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
    Hepatology. 2022;75:1338-1339.
    >> Share

  700. ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
    Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;75:1289-1299.
    >> Share

  701. PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
    Global burden of NAFLD and chronic liver disease among adolescents and young adults.
    Hepatology. 2022;75:1204-1217.
    >> Share

  702. KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
    Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
    Hepatology. 2022;75:1139-1153.
    >> Share

  703. ZHANG JL, Du BB, Zhang DH, Li H, et al
    OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
    Hepatology. 2022;75:1218-1234.
    >> Share

  704. SONG J, Song H, Wei H, Sun R, et al
    Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
    Hepatology. 2022;75:1181-1193.
    >> Share

  705. REN QN, Zhang H, Sun CY, Zhou YF, et al
    Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
    Hepatology. 2022;75:1123-1138.
    >> Share

  706. CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;75:1071-1072.
    >> Share

  707. QIN Y, Li A, Liu B, Gao M, et al
    Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
    Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
    >> Share

  708. SANGRO B, Argemi J
    Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
    >> Share

    April 2022
  709. SHAH PA, Patil R, Harrison SA
    NAFLD-related hepatocellular carcinoma: The growing challenge.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
    >> Share

  710. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
    >> Share

  711. YAN T, Luo Y, Yan N, Hamada K, et al
    Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
    Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
    >> Share

  712. CHEN L, Dong J, Meng Q, Song Z, et al
    Reply to the comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 19. doi: 10.1002/hep.32530.
    >> Share

  713. IVANICS T, Claasen MP, Patel MS, Hansen BE, et al
    Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 18. doi: 10.1002/hep.32532.
    >> Share

  714. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 17. doi: 10.1002/hep.32533.
    >> Share

  715. RAO Z, Li F, Guan Z, Zhou H, et al
    Comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32529.
    >> Share

  716. XU MX, Tan J, Ge CX, Dong W, et al
    TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32526.
    >> Share

  717. AHN JC, Lauzon M, Luu M, Noureddin M, et al
    Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32527.
    >> Share

  718. TRIPATHI D, Bureau C
    Prophylactic embolization of large spontaneous portosystemic shunts with TIPS: A panacea for post TIPS hepatic encephalopathy?
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32525.
    >> Share

  719. ZHU Y, Gu L, Lin X, Zhou X, et al
    P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis.
    Hepatology. 2022 Apr 10. doi: 10.1002/hep.32518.
    >> Share

  720. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    >> Share

  721. KHADERI S, Kanwal F
    Changing Epidemiology of Hepatocellular Cancer in the United States: winning the battle but it is not over yet.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32512.
    >> Share

  722. TCHORZ JS
    Re-tuning hepatocytes improves their functional engraftment.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32513.
    >> Share

  723. GOEPPERT B, Roessler S
    New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation.
    Hepatology. 2022 Apr 6. doi: 10.1002/hep.32509.
    >> Share

  724. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
    >> Share

  725. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Response to letter to the editor from Zhou et al (Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease).
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32503.
    >> Share

  726. ZHOU Y, Chu W, Wu X, Zhou H, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
    >> Share

  727. TOMLINSON JL, Ahn JC, Povero D, Ramkissoon R, et al
    Hepatology Highlights.
    Hepatology. 2022;75:775-776.
    >> Share

  728. AHUJA P, Bi X, Ng CF, Tse MCL, et al
    Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77- fibroblast growth factor 21 pathway.
    Hepatology. 2022 Apr 1. doi: 10.1002/hep.32501.
    >> Share

  729. SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
    Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
    Hepatology. 2022;75:1026-1037.
    >> Share

  730. SINGH SA, Madan K, Gupta S, Indrayan A, et al
    Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
    Hepatology. 2022;75:1067-1068.
    >> Share

  731. WANG S, Whitlock R, Lai JC, Taneja S, et al
    Reply.
    Hepatology. 2022;75:1068-1069.
    >> Share

  732. JAIN A, Sharma BC
    Reply.
    Hepatology. 2022;75:1066-1067.
    >> Share

  733. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
    Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
    Hepatology. 2022;75:1056-1057.
    >> Share

  734. PAILHORIES H, Boursier J, Diehl AM
    Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
    Hepatology. 2022;75:782-784.
    >> Share

  735. NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
    Banff consensus recommendations for steatosis assessment in donor livers.
    Hepatology. 2022;75:1014-1025.
    >> Share

  736. KWAN SY, Jiao J, Joon A, Wei P, et al
    Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
    Hepatology. 2022;75:955-967.
    >> Share

  737. ZHOU HZ, Li F, Cheng ST, Xu Y, et al
    DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
    Hepatology. 2022;75:847-865.
    >> Share

  738. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
    The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Hepatology. 2022;75:881-897.
    >> Share

    March 2022
  739. CULLARO G, Hsu CY, Lai JC
    Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
    >> Share

  740. LEE SH, Yim SY, Jeong YS, Li QX, et al
    Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32490.
    >> Share

  741. JAVITT NB
    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
    >> Share

  742. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    >> Share

  743. CAI HX, Xin C, Wang XP
    ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a murine model of Wilson's disease.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32484.
    >> Share

  744. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    >> Share

  745. D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
    Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
    >> Share

  746. CHEN L, Dong J, Liao S, Wang S, et al
    Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32471.
    >> Share

  747. FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
    Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
    >> Share

  748. CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
    Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
    >> Share

  749. HOU J
    Drinking vinegar, a potential adjuvant for immunotherapy of hepatocellular carcinoma?
    Hepatology. 2022 Mar 18. doi: 10.1002/hep.32463.
    >> Share

  750. GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
    Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
    >> Share

  751. LV Y, Chen H, Luo B, Bai W, et al
    Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
    >> Share

  752. BASS LM, Ye W, Hawthorne K, Leung DH, et al
    The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
    >> Share

  753. HU C, Xu B, Wang X, Wan WH, et al
    Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32449.
    >> Share

  754. FOERSTER F, Gairing SJ, Ilyas SI, Galle PR, et al
    Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32447.
    >> Share

  755. BARNAULT R, Verzeroli C, Fournier C, Michelet M, et al
    Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32446.
    >> Share

  756. HE Y, Luo J, Zhang G, Jin Y, et al
    Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32444.
    >> Share

  757. NIE YZ, Zheng YW, Taniguchi H
    Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32443.
    >> Share

  758. LU Z, Liu R, Wang Y, Jiao M, et al
    TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32442.
    >> Share

  759. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
    Diabetes Medications and Risk of Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439.
    >> Share


  760. Hepato Liver Cancer logy highlights.
    Hepatology. 2022;75:503-504.
    >> Share

  761. HILSCHER MB, Shah VH
    A NET gain in our understanding of acute liver failure.
    Hepatology. 2022;75:511-513.
    >> Share

  762. LUO MS, Huang GJ
    Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
    Hepatology. 2022;75:763-764.
    >> Share

  763. WU JW, Tseng TC, Kao JH
    Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.
    Hepatology. 2022;75:760-761.
    >> Share

  764. BEKKI Y, Fenig Y
    Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
    Hepatology. 2022;75:754.
    >> Share


  765. Seeking Editor for Clinical Liver Disease.
    Hepatology. 2022;75:i.
    >> Share

  766. VON MEIJENFELDT FA, Stravitz RT, Zhang J, Adelmeijer J, et al
    Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.
    Hepatology. 2022;75:623-633.
    >> Share

  767. GOIKOETXEA-USANDIZAGA N, Serrano-Macia M, Delgado TC, Simon J, et al
    Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
    Hepatology. 2022;75:550-566.
    >> Share

  768. REN R, He Y, Ding D, Cui A, et al
    Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.
    Hepatology. 2022;75:646-660.
    >> Share

  769. TAMAKI N, Imajo K, Sharpton S, Jung J, et al
    Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Hepatology. 2022;75:661-672.
    >> Share

  770. WANG C, Zhang L, Sun Z, Yuan X, et al
    Dedifferentiation-associated inflammatory factors of long-term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32436.
    >> Share

  771. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    >> Share

  772. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    >> Share

    February 2022
  773. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    >> Share

  774. SUTHEN SD, Lim CJ, Nguyen PHD, Dutertre CA, et al
    Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma.
    Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419.
    >> Share

  775. FAN L, Pan Q, Yang W, Koo SC, et al
    A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32412.
    >> Share

  776. IVANICS T, Murillo Perez CF, Claasen MP, Patel MS, et al
    Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32411.
    >> Share

  777. EFE C, Harputluoglu M, Karadag Soylu N, Yilmaz S, et al
    Liver transplantation following SARS-CoV-2 vaccination-induced liver failure.
    Hepatology. 2022 Feb 17. doi: 10.1002/hep.32409.
    >> Share

  778. WANG Z, Yu J, Liang P
    Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!"
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32402.
    >> Share

  779. JINDAL A, Mukund A
    Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32401.
    >> Share

  780. NOUREDDIN M, Abdelmalek MF
    ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
    >> Share

  781. YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
    Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
    >> Share

  782. ALVAREZ CS, Petrick JL, Parisi D, McMahon BJ, et al
    Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32394.
    >> Share

  783. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    >> Share

  784. ZANETTO A, Campello E, Spiezia L, Burra P, et al
    Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
    >> Share

  785. LEMOINE CP, Superina R
    Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
    >> Share

  786. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    >> Share

  787. LEE V, Wong TC
    Reply to "prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant".
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32379.
    >> Share

  788. WATKINS R, Ilyas SI, Penrice DD, Conboy CB, et al
    Hepatology Highlights.
    Hepatology. 2022;75:241-242.
    >> Share

  789. ROGAL S, Hansen L, Patel A, Ufere NN, et al
    AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
    Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
    >> Share

  790. KARATAYLI E, Lammert F
    Vulnerability to alcohol-associated liver disease: A tale of two systems.
    Hepatology. 2022;75:246-247.
    >> Share

  791. HEY P, Gow P
    Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion.
    Hepatology. 2022;75:495-496.
    >> Share

  792. GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
    Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
    Hepatology. 2022;75:379-390.
    >> Share

  793. VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
    Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    Hepatology. 2022;75:419-429.
    >> Share

  794. RAMANI K, Robinson AE, Berlind J, Fan W, et al
    S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.
    Hepatology. 2022;75:280-296.
    >> Share

  795. LIN T, Wang S, Munker S, Jung K, et al
    Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
    Hepatology. 2022;75:322-337.
    >> Share

  796. KIM KY, Kim JO, Kim YS, Choi JE, et al
    Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.
    Hepatology. 2022;75:391-402.
    >> Share

    January 2022
  797. JIANG SY, Yang X, Yang Z, Li JW, et al
    Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32381.
    >> Share

  798. DE A, Keisham A, Duseja A
    Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
    >> Share

  799. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    >> Share

  800. KUMAR A, Sharma P, Arora A
    Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
    >> Share

  801. LIU F, Zhang W, Liu H
    Letter to the Editor: Hepatocyte Proliferation Peak and beta-Oxidation in Liver Regeneration after Partial Hepatectomy.
    Hepatology. 2022 Jan 26. doi: 10.1002/hep.32357.
    >> Share

  802. PAIK JM, Henry L, Younossi ZM
    Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. Hepatology 2022.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32362.
    >> Share

  803. SAHAI P, Jindal A, Mukund A
    Letter to the Editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32354.
    >> Share

  804. LI YT, Liu CJ, Kao JH, Lin LF, et al
    Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally Through Novel RNA Binding Function.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32356.
    >> Share

  805. HAN J, Wang B, Liu W, Wang S, et al
    Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32355.
    >> Share

  806. FANG Y, Liu W, Tang Z, Ji X, et al
    MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.
    Hepatology. 2022 Jan 19. doi: 10.1002/hep.32348.
    >> Share

  807. KHATIB SA, Ma L, Dang H, Forgues M, et al
    Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32345.
    >> Share

  808. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    >> Share

  809. WU T, Simonetto DA, Halamka JD, Shah VH, et al
    The Digital Transformation of Hepatology: The Patient is Logged In.
    Hepatology. 2022 Jan 13. doi: 10.1002/hep.32329.
    >> Share

  810. JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
    Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
    >> Share

  811. RAMADORI P, Kam S, Heikenwalder M
    T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336.
    >> Share

  812. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
    >> Share

  813. WANG Z, Liu M, Zhang DZ, Wu SS, et al
    Microwave Ablation versus Laparoscopic Resection as First-line Therapy for Solitary 3-5 cm Hepatocellular Carcinoma.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32323.
    >> Share

  814. FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
    Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
    >> Share

  815. MA H, Kang Z, Foo TK, Shen Z, et al
    Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335.
    >> Share

  816. ANDERSSON ER
    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
    >> Share

  817. MOORE MP, Cunningham RP, Meers GM, Johnson SA, et al
    Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
    Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324.
    >> Share

  818. TRANAH TH, Shawcross DL
    The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32319.
    >> Share

  819. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    >> Share

  820. NG CH, Xiao J, Lim WH, Chin YH, et al
    Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
    >> Share

  821. WU H, Li Y, Shi G, Du S, et al
    Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32316.
    >> Share


  822. Hepatology Highlights.
    Hepatology. 2022;75:1-2.
    >> Share

  823. PHAM L, Kennedy L, Baiocchi L, Meadows V, et al
    Mast cells in liver disease progression: An update on current studies and implications.
    Hepatology. 2022;75:213-218.
    >> Share

    December 2021
  824. LABENZ C, Labenz J, Galle PR
    Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis?
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32309.
    >> Share

  825. RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
    Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
    >> Share

  826. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    >> Share

  827. LAEMMLE A, Haberle J, Willenbring H
    Reply to "The Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency".
    Hepatology. 2021 Dec 21. doi: 10.1002/hep.32290.
    >> Share

  828. KODAMA T, Takehara T
    Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
    >> Share

  829. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    >> Share

  830. RICH NE, Singal AG
    Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32284.
    >> Share

  831. FRIEDMAN SL, Pinzani M
    Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
    >> Share

  832. CARABALLO GALVA LD, Jiang X, Hussein MS, Zhang H, et al
    Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma.
    Hepatology. 2021 Dec 12. doi: 10.1002/hep.32279.
    >> Share

  833. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
    >> Share

  834. LAI JC, Shui AM, Duarte-Rojo A, Ganger DR, et al
    Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32268.
    >> Share

  835. XIN B, Yang M, Wu P, Du L, et al
    Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32266.
    >> Share

  836. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    >> Share

  837. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
    Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
    >> Share


  838. 2021 Hepatology Referees (Volumes 73 and 74).
    Hepatology. 2021;74:3565-3569.
    >> Share

  839. CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2931-2934.
    >> Share

  840. KUMAR K, Kulkarni A, Jagdish RK
    Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
    Hepatology. 2021;74:3559-3560.
    >> Share

  841. AGARWAL A, Sharma S, Saraya A
    Letter to the Editor: Defining the Futility for Rescue Transjugular Intrahepatic Portosystemic Shunt Using the Model for End-Stage Liver Disease Score and Lactate in Variceal Bleed.
    Hepatology. 2021;74:3556-3557.
    >> Share

  842. JINDAL A, Sarin SK, Mukund A
    Letter to the Editor: Salvage TIPS for Refractory Variceal Bleed-More Questions Than Answers!
    Hepatology. 2021;74:3557-3558.
    >> Share

  843. VALENTI LVC, Cherubini A
    To Be or Not to Be: The Quest for Patatin-Like Phospholipase Domain Containing 3 p.I148M Function.
    Hepatology. 2021;74:2942-2944.
    >> Share

  844. GOH GB, Chan WK, Wong VW
    Breastfeeding to Prevent NAFLD.
    Hepatology. 2021;74:2939-2941.
    >> Share

  845. SONG J, Liu Y, Wan J, Zhao GN, et al
    SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
    Hepatology. 2021;74:3091-3109.
    >> Share

  846. WAN J, Zhang Y, Yang D, Liang Y, et al
    Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021;74:3074-3090.
    >> Share

  847. TILSON SG, Morell CM, Lenaerts AS, Park SB, et al
    Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Hepatology. 2021;74:2998-3017.
    >> Share

  848. SHAH NL, Miller JB, Kalman RS, Kumar S, et al
    AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee.
    Hepatology. 2021;74:2935-2938.
    >> Share

  849. PARK Y, Sinn DH, Oh JH, Goh MJ, et al
    The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
    Hepatology. 2021;74:2988-2997.
    >> Share

  850. WU T, Luo G, Lian Q, Sui C, et al
    Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
    Hepatology. 2021;74:3249-3268.
    >> Share

  851. KUMAR S, Wong R, Newberry C, Yeung M, et al
    Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD.
    Hepatology. 2021;74:3472-3478.
    >> Share

  852. OTT P, Ala A, Askari FK, Czlonkowska A, et al
    Designing Clinical Trials in Wilson's Disease.
    Hepatology. 2021;74:3460-3471.
    >> Share

  853. GARCIA-MACIA M, Santos-Ledo A, Leslie J, Paish HL, et al
    A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
    Hepatology. 2021;74:3441-3459.
    >> Share

  854. LANGE AP, Usmani AA, Wald C, Gordon FD, et al
    Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.
    Hepatology. 2021;74:3539-3541.
    >> Share

  855. HAKIM A, Moll M, Brancale J, Liu J, et al
    Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
    Hepatology. 2021;74:3394-3408.
    >> Share

  856. BAI W, Al-Karaghouli M, Stach J, Sung S, et al
    Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
    Hepatology. 2021;74:3301-3315.
    >> Share

  857. RUSYN I, Arzuaga X, Cattley RC, Corton JC, et al
    Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.
    Hepatology. 2021;74:3486-3496.
    >> Share

    November 2021
  858. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
    "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
    >> Share

  859. GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
    Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
    Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
    >> Share

  860. LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
    Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
    Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
    >> Share

  861. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
    >> Share

  862. KIM ER, Park JS, Kim JH, Oh JY, et al
    A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
    >> Share

  863. TIAN L, Zhao L, Sze KM, Kam CS, et al
    Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
    >> Share

  864. YANG J, Ye J, Ma T, Tang F, et al
    TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
    >> Share

  865. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    >> Share

  866. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    >> Share

  867. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    >> Share

  868. KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2329-2332.
    >> Share